• Ohio Ambassadors
• Work-Life Balance
  • Work-Life Resources
• Success Stories
  • Ad Campaigns
  • Interviews with Ohio Executives
  • Interviews with Ohio Employees
  • Executive Spouse Interviews
• Social Media
• Discover Ohio
• Living in Ohio
  • Outdoor Recreation in Ohio
  • Performing Arts in Ohio
  • Museums and Galleries in Ohio
  • Professional Sports in Ohio
  • Low Cost of Living in Ohio
• Shop Ohio Online

Arteriocyte

For Tony Pietromica, returning to Ohio was a life-changing experiment.

After years of living on the East Coast, returning to Ohio for his MBA became an experiment for Tony Pietromica and his family. Fully prepared to move back East, they were pleasantly surprised to find both their career satisfaction and quality of life improved in the Buckeye state.

With his extensive experience in bioinformatics, Tony seized an exciting opportunity with Arteriocyte Inc., a newly formed Cleveland biotech company. Arteriocyte is developing adult stem cell therapies to treat ischemia in patients suffering from a variety of circulatory ailments. Ohio's outstanding community of universities and research institutions provides an ideal location. And the company has found that doing business in Ohio is much more cost effective than on the coast, speeding up its growth. In fact, Arteriocyte was able to enter its first clinical trial early this year.

The Pietromicas quickly discovered that East Coast stereotypes of Ohio were without merit. They were able to cut their living expenses in half while increasing the space and amenities of their home. Restaurants, activities and entertainment choices have exceeded expectations. And the relaxed pace and easy commute give them more time to spend with good friends and family and enjoy their hobbies. There's no going back. The Pietromicas are proud Ohioans once again.

About Arteriocyte

Arteriocyte is a clinical stage research and development biotechnology company based in Cleveland, Ohio that is developing proprietary, adult stem cell-based therapies for the treatment of ischemic diseases or where ischemia is the underlying culprit in the progression of that disease. These diseases include coronary artery disease, peripheral vascular disease, vascular complications of diabetes and neurodegenerative conditions that are exacerbated because of poor blood flow. The company's first clinical therapeutic (ACY001) entered human safety evaluation in the US in 2006 for the treatment of chronic coronary ischemia. For more information, please visit www.arteriocyte.com.